WO2021114864A1 - DÉRIVÉ DE β-CARBOLINE CYCLOCÉTÈNE BASÉ SUR UNE RÉPONSE DOUBLE AU PH ET GSH ET UTILISATION ASSOCIÉE - Google Patents
DÉRIVÉ DE β-CARBOLINE CYCLOCÉTÈNE BASÉ SUR UNE RÉPONSE DOUBLE AU PH ET GSH ET UTILISATION ASSOCIÉE Download PDFInfo
- Publication number
- WO2021114864A1 WO2021114864A1 PCT/CN2020/121436 CN2020121436W WO2021114864A1 WO 2021114864 A1 WO2021114864 A1 WO 2021114864A1 CN 2020121436 W CN2020121436 W CN 2020121436W WO 2021114864 A1 WO2021114864 A1 WO 2021114864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- pyrido
- carbamate
- indole
- oxocyclohex
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title claims abstract description 6
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title abstract description 18
- 230000035440 response to pH Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 230000004044 response Effects 0.000 claims abstract description 9
- -1 methoxy, ethoxy Chemical group 0.000 claims description 88
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 238000002360 preparation method Methods 0.000 claims description 59
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- FJYXMGWCOCMTFU-UHFFFAOYSA-N (6-oxocyclohexen-1-yl) N-methyl-N-[1-(4-methylphenyl)-9H-pyrido[3,4-b]indol-3-yl]carbamate Chemical compound CC1=CC=C(C=C1)C2=C3C(=CC(=N2)N(C)C(=O)OC4=CCCCC4=O)C5=CC=CC=C5N3 FJYXMGWCOCMTFU-UHFFFAOYSA-N 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 10
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 125000003277 amino group Chemical group 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 238000002626 targeted therapy Methods 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 65
- 238000000034 method Methods 0.000 description 49
- 239000007787 solid Substances 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- 238000001308 synthesis method Methods 0.000 description 38
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 35
- 229960003180 glutathione Drugs 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 230000003595 spectral effect Effects 0.000 description 22
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002189 fluorescence spectrum Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 238000001506 fluorescence spectroscopy Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FUGYSQRKKIFVOO-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC=1C=C(C=C(C=1OC)OC)C1=NC(=CC2=C1NC1=CC=CC=C21)N FUGYSQRKKIFVOO-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XAKXBBZTTCITLF-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC1=CC(=C(C=C1)C2=C3C(=CC(=N2)N)C4=CC=CC=C4N3)OC XAKXBBZTTCITLF-UHFFFAOYSA-N 0.000 description 2
- LXBLFJFVGBLXCY-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC=1C=C(C=CC=1OC)C1=NC(=CC2=C1NC1=CC=CC=C21)N LXBLFJFVGBLXCY-UHFFFAOYSA-N 0.000 description 2
- OBWFGMSOGOUCLC-UHFFFAOYSA-N 1-(3-methoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC=1C=C(C=CC=1)C1=NC(=CC2=C1NC1=CC=CC=C21)N OBWFGMSOGOUCLC-UHFFFAOYSA-N 0.000 description 2
- QQMQOTCQWRBSDN-UHFFFAOYSA-N 1-(4-methoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC1=CC=C(C=C1)C1=NC(=CC2=C1NC1=CC=CC=C21)N QQMQOTCQWRBSDN-UHFFFAOYSA-N 0.000 description 2
- DDRUWHYIZXPQMJ-UHFFFAOYSA-N 1-(4-methylphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound CC1=CC=C(C=C1)C1=NC(=CC2=C1NC1=CC=CC=C21)N DDRUWHYIZXPQMJ-UHFFFAOYSA-N 0.000 description 2
- QMDIIXACBPZLCK-UHFFFAOYSA-N 2-(hydroxymethyl)cyclohex-2-en-1-one Chemical compound OCC1=CCCCC1=O QMDIIXACBPZLCK-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 0 C*(C*(C)C=C1COC(Nc2nc(C3=CC=C*C=C3)c3[n](*)c(cccc4)c4c3c2)=O)CC1=O Chemical compound C*(C*(C)C=C1COC(Nc2nc(C3=CC=C*C=C3)c3[n](*)c(cccc4)c4c3c2)=O)CC1=O 0.000 description 2
- FLGPZAUDAYFEGI-UHFFFAOYSA-N C1CC=C(C(=O)C1)COC(=O)OC2=CC=C(C=C2)[N+](=O)[O-] Chemical compound C1CC=C(C(=O)C1)COC(=O)OC2=CC=C(C=C2)[N+](=O)[O-] FLGPZAUDAYFEGI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- BXGZXFNSZXHQOA-UHFFFAOYSA-N methyl 1-(3,4,5-trimethoxyphenyl)-9h-pyrido[3,4-b]indole-3-carboxylate Chemical compound N=1C(C(=O)OC)=CC=2C3=CC=CC=C3NC=2C=1C1=CC(OC)=C(OC)C(OC)=C1 BXGZXFNSZXHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IEHOZGNJPAUOGM-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC1=CC(=C(C=C1)OC)C2=C3C(=CC(=N2)N)C4=CC=CC=C4N3 IEHOZGNJPAUOGM-UHFFFAOYSA-N 0.000 description 1
- CTHWWYOSYQUXJY-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)-9h-pyrido[3,4-b]indole Chemical compound COC1=C(OC)C(OC)=CC(C=2C=3NC4=CC=CC=C4C=3C=CN=2)=C1 CTHWWYOSYQUXJY-UHFFFAOYSA-N 0.000 description 1
- CNQXNCUTUZGTEM-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-amine Chemical compound COC=1C=C(C=C(C=1)OC)C1=NC(=CC2=C1NC1=CC=CC=C21)N CNQXNCUTUZGTEM-UHFFFAOYSA-N 0.000 description 1
- MWKPNYZOQNIQJS-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-9h-pyrido[3,4-b]indole Chemical compound COC1=CC(OC)=CC(C=2C=3NC4=CC=CC=C4C=3C=CN=2)=C1 MWKPNYZOQNIQJS-UHFFFAOYSA-N 0.000 description 1
- BDXJANJAHYKTMI-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-pyrrole Chemical compound CC=1NC(C)=C(C)C=1C BDXJANJAHYKTMI-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- TXQAZWIBPGKHOX-UHFFFAOYSA-N Indole-3-amine Natural products C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- ILHCNKVSURBSFC-QHHAFSJGSA-N cyclohexen-1-ylmethyl (E)-but-2-enoate Chemical compound C\C=C\C(=O)OCC1=CCCCC1 ILHCNKVSURBSFC-QHHAFSJGSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003394 isomerase inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
Definitions
- human cytoplasmic GSTs can be divided into 7 subtypes, namely: ⁇ , ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- GST ⁇ is related to human tissue cell canceration, Tumor formation and the generation of tumor drug resistance are closely related.
- Studies have shown that in a variety of tumor cells (such as breast cancer, colon cancer tumor cells) and drug-resistant tumors, GST ⁇ is overexpressed.
- the formation of GST ⁇ is considered to be one of the signs of liver cancer.
- This characteristic of GST ⁇ makes it an important target in the design of anti-tumor drug prodrugs. In view of this, the use of the highly expressed GST ⁇ in tumor tissues to develop and design cancer chemotherapeutic drugs and probes has great application value.
- the present invention is based on the structural modification of the natural indole alkaloid ⁇ -carboline with anti-tumor activity.
- the ⁇ -carboline is connected to the cycloketene through a carbamate bond, and electron donors are introduced into the structure of the ⁇ -carboline.
- the group can not only produce pH-sensitive fluorescence, but also release fluorescence at 492nm after covalently binding to GSH. It also targets GST ⁇ , which significantly enhances the compound’s anti-tumor proliferation and metastasis activity, achieving early cancer diagnosis and precise treatment. Double targeting effect.
- R 1 or R 2 are the same or different and represent one or more substituents on the corresponding substituted ring, selected from one of H, amino, halogen, hydroxyl, nitro, alkoxy, alkyl, alkylamino or There are several types, when R 1 or R 2 each represents multiple substituents, the substituents are the same or different;
- R 4 is selected from H, alkyl, methoxyalkyl or
- Another object of the present invention is to provide a preparation method of the compound of the general formula of the present invention, which comprises the following steps:
- Example 1 (6-oxocyclohex-1-en-1-yl)methyl(1-(3,4,5-trimethoxyphenyl)-9H-pyrido[3,4-b]indino Dol-3-yl) carbamate (I 1 ) or bis(6-oxocyclohex-1-en-1-yl)methyl (1-(3,4,5-trimethoxyphenyl) Preparation of -9H-pyrido[3,4-b]indol-3-yl)carbamate (II 1)
- Example 6 (6-oxocyclohex-1-en-1-yl)methyl(1-(2,4-dimethoxyphenyl)-9H-pyrido[3,4-b]indole -3-yl) carbamate (I 6 ) or bis(6-oxocyclohex-1-en-1-yl)methyl(1-(2,4-dimethoxyphenyl)-9H -Pyrido[3,4-b]indol-3-yl) carbamate (II 6 ) preparation
- Example 14 Study on the determination of the tumor cell proliferation inhibition rate of the compound of the present invention by the MTT method
- the compounds of this invention I 1 -I 13 and II 1 -II 13 at 1 ⁇ M concentration, with the increase of GSH equivalents, characterized in UV absorption peak wavelength gradually decreases between 385 ⁇ 430nm, gradually rises at the peak of 435 ⁇ 470nm ; Its fluorescence spectrum shows that the fluorescence at 470 ⁇ 530nm also gradually increases with the increase of GSH equivalent.
- the specific experimental method is as follows: Dissolve 1 ⁇ M of the series of compounds in an aqueous solution containing a catalytic amount of GST ⁇ , and add 1mM K + , Na + , Ca 2+ , Mg 2+ , Zn 2+ , Al 3+ , Cu to it 2+ , Fe 2+ ; 100 ⁇ M GSH, lysine, histidine, alanine, cysteine, glutamic acid, serine, glycine, arginine, vitamin C, Na 2 S, H 2 O 2. Bio-endogenous substances such as NADH. All emission spectra were recorded after incubation at 37°C for 0.5 hours, excitation at 430-480nm, and recording at 450nm to 650nm.
- Fig. 5 is the result of in vivo fluorescence imaging distribution of compound I 1 of the present invention, which shows that the compound of the present invention can selectively show strong fluorescence signals in tumor tissues in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne un dérivé de β-carboline-cyclocétène, qui a la structure représentée par la formule générale (I). Un dérivé de β-carboline-cyclocétène de type nouveau est conçu et synthétisé par introduction d'un groupe donneur d'électrons à une position appropriée de β-carboline, et la liaison de cyclocétène, qui a une activité antitumorale, au moyen du groupe amino en position 3 de β-carboline et à l'aide d'une liaison carbamate. Le composé peut réaliser, non seulement une imagerie par fluorescence pour une réponse double à un pH et à un GSH et un diagnostic dans un microenvironnement tumoral, mais peut cibler de manière sélective GSTπ, qui est fortement exprimé dans les tissus tumoraux, pour inhiber de manière significative la prolifération des cellules tumorales. La fluorescence à double réponse pH/GSH et le traitement et le diagnostic du cancer ciblés fournissent un nouveau choix pour un diagnostic tumoral précis et une thérapie ciblée, et permettent d'élargir l'utilisation de molécules multifonctionnelles dans un médicament de précision.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020356793A AU2020356793B2 (en) | 2019-12-09 | 2020-10-16 | PH/glutathione-responsive β-carbolines/cycloketene derivatives and their preparation and application |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911256603.7A CN110981870B (zh) | 2019-12-09 | 2019-12-09 | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 |
| CN201911256603.7 | 2019-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021114864A1 true WO2021114864A1 (fr) | 2021-06-17 |
Family
ID=70091692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/121436 WO2021114864A1 (fr) | 2019-12-09 | 2020-10-16 | DÉRIVÉ DE β-CARBOLINE CYCLOCÉTÈNE BASÉ SUR UNE RÉPONSE DOUBLE AU PH ET GSH ET UTILISATION ASSOCIÉE |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN110981870B (fr) |
| AU (1) | AU2020356793B2 (fr) |
| WO (1) | WO2021114864A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113512022A (zh) * | 2021-06-29 | 2021-10-19 | 西安交通大学 | 一种基于pH响应的多功能荧光链接体及制备方法和应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110981870B (zh) * | 2019-12-09 | 2020-11-24 | 南通大学 | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 |
| CN111925369B (zh) * | 2020-08-18 | 2021-09-28 | 南通大学 | 一类β-咔啉氰基呋喃衍生物及其制备方法与应用 |
| CN111892594B (zh) * | 2020-08-26 | 2022-05-13 | 南通大学 | 含取代吡唑单元的1-(3,4,5-三甲氧基苯基)-β-咔啉酰腙的制备与应用 |
| CN111961049B (zh) * | 2020-08-26 | 2022-07-01 | 南通大学 | 含1,3-二甲基-5-芳氧基吡唑的β-咔啉衍生物及其制备方法和用途 |
| CN113717169B (zh) * | 2021-09-03 | 2022-05-17 | 南通大学 | N,N二苯基氨基修饰的β-咔啉吲哚鎓盐、制备方法与应用 |
| CN114409594B (zh) * | 2021-10-24 | 2023-09-26 | 济南大学 | 靶向高尔基体的谷胱甘肽比率荧光探针、制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145705A (zh) * | 2012-06-14 | 2013-06-12 | 南通大学 | β-咔啉类生物碱衍生物、其制备方法及其医药用途 |
| CN103880842A (zh) * | 2014-02-20 | 2014-06-25 | 南通大学 | 具HDAC抑制活性的β-咔啉类衍生物及制备方法和用途 |
| CN106432235A (zh) * | 2016-10-19 | 2017-02-22 | 南通大学 | 靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途 |
| CN110981870A (zh) * | 2019-12-09 | 2020-04-10 | 南通大学 | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 |
-
2019
- 2019-12-09 CN CN201911256603.7A patent/CN110981870B/zh active Active
-
2020
- 2020-10-16 WO PCT/CN2020/121436 patent/WO2021114864A1/fr active Application Filing
- 2020-10-16 AU AU2020356793A patent/AU2020356793B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145705A (zh) * | 2012-06-14 | 2013-06-12 | 南通大学 | β-咔啉类生物碱衍生物、其制备方法及其医药用途 |
| CN103880842A (zh) * | 2014-02-20 | 2014-06-25 | 南通大学 | 具HDAC抑制活性的β-咔啉类衍生物及制备方法和用途 |
| CN106432235A (zh) * | 2016-10-19 | 2017-02-22 | 南通大学 | 靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途 |
| CN110981870A (zh) * | 2019-12-09 | 2020-04-10 | 南通大学 | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 |
Non-Patent Citations (2)
| Title |
|---|
| LING YONG, XU CHENJUN, LUO LIN, CAO JINGYI, FENG JIAO, XUE YU, ZHU QING, JU CAOYUN, LI FENGZHI, ZHANG YIHUA, ZHANG YANAN, LING XIA: "Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 23, 10 November 2015 (2015-11-10), pages 9214 - 9227, XP055820242, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01052 * |
| REIKO IKEDA, TOSHIE IWAKI, TOMOKO IIDA, TAKASUMIOKABAYASHI, EISHIRO NISHI, MASAKI KUROSAWA, NORIO SAKAI, TAKEO KONAKAHARA: "3-Benzylamino-β-carboline derivatives induce apoptosis through G2/M arrest in human carcinoma cells HeLa S-3", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 2, 1 February 2011 (2011-02-01), pages 636 - 646, XP055820237, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2010.11.044 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113512022A (zh) * | 2021-06-29 | 2021-10-19 | 西安交通大学 | 一种基于pH响应的多功能荧光链接体及制备方法和应用 |
| CN113512022B (zh) * | 2021-06-29 | 2023-05-16 | 西安交通大学 | 一种基于pH响应的多功能荧光链接体及制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020356793A1 (en) | 2021-06-24 |
| CN110981870A (zh) | 2020-04-10 |
| AU2020356793B2 (en) | 2021-08-05 |
| CN110981870B (zh) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021114864A1 (fr) | DÉRIVÉ DE β-CARBOLINE CYCLOCÉTÈNE BASÉ SUR UNE RÉPONSE DOUBLE AU PH ET GSH ET UTILISATION ASSOCIÉE | |
| US7994159B2 (en) | c-Kit kinase inhibitor | |
| WO2017202276A1 (fr) | Dérivé de phénylate, procédé pour sa préparation et composition pharmaceutique et utilisations correspondantes | |
| ES2549397T3 (es) | Compuestos farmacocinéticamente mejorados | |
| KR20180058737A (ko) | 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체 | |
| MX2007008372A (es) | Ureas disustituidas como inhibidores de cinasa. | |
| TW201825510A (zh) | 細胞穿透肽序列 | |
| JP5636091B2 (ja) | 癌治療に用いるためのコンブレタスタチン類似体 | |
| WO2021249234A1 (fr) | Dérivé de benzothiazole et son utilisation | |
| CN102796124A (zh) | 双β-咔啉碱类化合物、其制法和其药物组合物与用途 | |
| EP2924042A1 (fr) | Composé bis- -carboline et procédé de préparation, composition pharmaceutique et utilisation associée | |
| CN103502219A (zh) | 作为治疗剂的新型小分子 | |
| TW202039439A (zh) | ４（１ｈ）－奎諾酮衍生物及其用途 | |
| JP2005281309A (ja) | 新規な融合ピラゾリル化合物 | |
| WO2022199547A1 (fr) | Dérivé de 7,9-dihydropurine et son usage pharmaceutique | |
| TW201922709A (zh) | 表皮生長因子受體抑制劑 | |
| JP2013515766A (ja) | イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物 | |
| WO2015021894A1 (fr) | Nouveau dérivé d'acide hydroximique et son application médicale | |
| CN110551102B (zh) | Alk共价抑制剂及其用途 | |
| CN104230912B (zh) | 喹啉衍生物、其制备方法及其用途 | |
| JP2005532280A (ja) | 化合物 | |
| CN110467616B (zh) | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 | |
| WO2015085860A1 (fr) | Composé hétérocyclique d'acide hydroxamique, composition pharmaceutique et application associées | |
| CN111196922B (zh) | pH敏感型β-咔啉衍生物荧光探针在肿瘤荧光成像中的应用 | |
| CN104177377B (zh) | 3位双胺β-咔啉碱类化合物、其制法和其药物组合物与用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref document number: 2020356793 Country of ref document: AU Date of ref document: 20201016 Kind code of ref document: A |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20899332 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20899332 Country of ref document: EP Kind code of ref document: A1 |